

30 April 2025

Oxford Nanopore Technologies plc
(the "Company")

Publication of 2024 Annual Report and Notice of Annual General Meeting

Oxford Nanopore Technologies plc (LSE:ONT), the company behind a new generation of nanopore-based sequencing technology, today announces that it has published its Annual Report and Accounts for the year ended 31 December 2024 and its Notice of Annual General Meeting 2025.

In compliance with Listing Rule 9.6.1, copies of the following documents have been submitted to the National Storage Mechanism and will shortly be available for inspection at:

<https://www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism>

- Annual Report and Accounts for the year ended 31 December 2024 ("**2024 ARA**"); and
- Notice of Annual General Meeting 2025 ("**2025 AGM Notice**").

Printed copies of the 2024 ARA and 2025 AGM Notice, together with the Form of Proxy for use in connection with the 2025 Annual General Meeting, have been posted to shareholders who have elected to receive hard copies. Electronic copies of the 2024 ARA and 2025 AGM Notice are available on the Investor Relations section of the Company's website at <https://nanoporetech.com/about-us/investors>.

The 2025 Annual General Meeting will be held at the Company's offices at Gosling Building, Edmund Halley Road, Oxford Science Park, Oxford, OX4 4DQ at 10:30am on Wednesday, 4 June 2025. Details including how shareholders can vote by proxy and ask questions in advance of the meeting can be found in the 2025 AGM Notice. The Board also encourages all shareholders to submit a proxy vote in advance of the AGM. We recommend voting online via www.shareview.co.uk by logging in, selecting 'View' on the 'My Investments' page and then click on the link to vote and follow the on-screen instructions.

Explanatory note

For the purposes of complying with the Disclosure and Transparency Rules, the 2024 ARA being submitted to the National Storage Mechanism contains the following regulated information in unedited form:

- The principal risks and uncertainties facing the Company;
- The Directors' responsibility statement made in respect of the Financial Statements and Directors' Report contained in the 2024 ARA; and
- A statement regarding related party transactions.

-ENDS-

For further information please contact:

cosec@nanoporetech.com

ir@nanoporetech.com

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used in more than 125 countries to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more information, please visit: <https://nanoporetech.com/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOABUGDSBGDDGUC